Reporting in the Oct. 14 issue of The American Journal of Medicine, Kristopher Ahn, M.D., and Rukma Govindu, M.D., describe a case of an otherwise healthy 36-year-old African American woman who presents to the emergency department for treatment of a long-lasting skin rash. As her ED visit unfolds, it turns into a complicated, challenging, difficult to diagnose case. Learn more in this featured case study.
IL-1 inhibition with anakinra was more effective than TNFi treatment for improving glycemic and inflammatory parameters in patients with rheumatoid arthritis and type 2 diabetes, say researchers writing in PLOS Medicine last month.
In this week's Rheumatology Network news roundup, we highlight advances in rheumatology research featured in recent issues of the New England Journal of Medicince, the journal Rheumatology and others. Among the most interesting findings was a study that highlights a link between antibiotic use and rheumatoid arthritis. Learn more in this slidesshow.
Patients with rheumatoid arthritis have a large comorbidity burden at the time of diagnosis, including chronic obstructive pulmonary disease (COPD), asthma and interstitial lung disease, but COPD is a particular concern, say researchers writing in Rheumatology this month.
Exposure to antibiotics increases the risk of developing rheumatoid arthritis, say researchers writing in the journal Rheumatology this month.
A review in the journal Lupus examines treatments for primary and secondary thromboprophylaxis in patients with anti-phospholipid autoantibodies (aPL) and a history of thrombosis, which can affect more than 50 percent of people with systemic lupus erythematosus.
In a review that examines the use of conventional and orphan autoantibodies as biomarkers for diagnosing systemic lupus erythematosus (SLE), researchers say the science is advancing rapidly with the goal of diagnosing lupus earlier than currently done.
Total hip arthroplasty does not provide a clinically significant improvement over hemiarthroplasty in function and quality of life over 24 months, shows a NEJM study. The incidence of secondary procedures did not differ significantly between the two groups.
Vedolizumab proves to be superior to adalimumab for in achieving clinical remission and endoscopic improvement for ulcerative colitis, but not corticosteroid-free clinical remission.
Ustekinumab (Stelara, Janssen Biotech) was more effective at one year than placebo for inducing and maintaining remission in patients with moderate-to-severe ulcerative colitis, NEJM study shows.